News

Net revenues were $4.9bn for the first quarter of 2013 compared to $5.1bn for the first quarter of 2012. Teva president and chief executive officer Dr. Jeremy Levin

Nymox CEO Paul Averback said, "Final completion of enrollment in this last major pivotal U.S. study is an important milestone in the NX-1207 development pathway. We look forward

Nasal spray, oral spray and nasal swab delivery form products, which will be manufactured by Oasis Health, to offer relief and treatment of nausea. Itonis Pharmaceuticals founding member

The collaboration will leverage Ambrx’s protein medicinal chemistry technology. Ambrx chief executive officer Lawson Macartney said it is the third collaboration to include another aspect of the technology

Liptruzet, administered once per day when diet alone is not sufficient, contains Ezetimibe, efficacious LDL cholesterol lowering therapy, and atorvastatin, a statin. Two sources of cholesterol can be

The study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 Type 2 diabetic patients. Clinical & Regulatory

The program is focused on small molecules that prevent a receptor called CSF-1R or cFMS in the body that plays a major role in the immune response to

Prenoxad Injection is a prescription only medicine (POM) that contains a solution of naloxone hydrochloride. It is used for emergency for either complete or partial reversal of life-threatening

The injection is used in lymphatic mapping procedures that help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. The US Food